eClinical Solutions Market Size to Hit USD 25.85 Bn by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on EClinical Solutions Market

5.1. COVID-19 Landscape: EClinical Solutions Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global EClinical Solutions Market, By Solution Type

8.1. EClinical Solutions Market, by Solution Type

8.1.1. Electronic Data Capture (EDC)

8.1.1.1. Market Revenue and Forecast

8.1.2. Clinical Data Management Systems (CDMS)

8.1.2.1. Market Revenue and Forecast

8.1.3. Clinical Trial Management Systems (CTMS)

8.1.3.1. Market Revenue and Forecast

8.1.4. Randomization and Trial Supply Management (RTSM)

8.1.4.1. Market Revenue and Forecast

8.1.5. Electronic Patient Reported Outcomes (ePRO)

8.1.5.1. Market Revenue and Forecast

8.1.6. Electronic Clinical Outcome Assessment (eCOA)

8.1.6.1. Market Revenue and Forecast

8.1.7. Electronic Patient Reported Outcomes (ePRO)

8.1.7.1. Market Revenue and Forecast

8.1.8. Clinical Analytics Platforms

8.1.8.1. Market Revenue and Forecast

8.1.9. Clinical Data Integration Platforms

8.1.9.1. Market Revenue and Forecast

8.1.10. Electronic Patient Reported Outcomes (ePRO)

8.1.10.1. Market Revenue and Forecast

8.1.11. eConsent

8.1.11.1. Market Revenue and Forecast

8.1.12. Safety Solutions (pharmacovigilance platforms)

8.1.12.1. Market Revenue and Forecast

8.1.13. Regulatory Information Management (RIM)

8.1.13.1. Market Revenue and Forecast

8.1.14. Risk-Based Monitoring (RBM)

8.1.14.1. Market Revenue and Forecast

8.1.15. Medical Imaging Solutions

8.1.15.1. Market Revenue and Forecast

8.1.16. Electronic Trial Master File (eTMF)

8.1.16.1. Market Revenue and Forecast

8.1.17. Wearable/Remote Monitoring Devices Integration

8.1.17.1. Market Revenue and Forecast

8.1.18. Artificial Intelligence/Machine Learning in eClinical

8.1.18.1. Market Revenue and Forecast

Chapter 9. Global EClinical Solutions Market, By Development Phase

9.1. EClinical Solutions Market, by Development Phase

9.1.1. Phase IV

9.1.1.1. Market Revenue and Forecast

9.1.2. Phase III

9.1.2.1. Market Revenue and Forecast

9.1.3. Phase II

9.1.3.1. Market Revenue and Forecast

9.1.4. Phase I

9.1.4.1. Market Revenue and Forecast

Chapter 10. Global EClinical Solutions Market, By Delivery Mode

10.1. EClinical Solutions Market, by Delivery Mode

10.1.1. Web-based / Cloud-based Solutions

10.1.1.1. Market Revenue and Forecast

10.1.2. On-Premise Solutions

10.1.2.1. Market Revenue and Forecast

10.1.3. Hybrid Deployment Models

10.1.3.1. Market Revenue and Forecast

Chapter 11. Global EClinical Solutions Market, By Clinical Trial Phase

11.1. EClinical Solutions Market, by Clinical Trial Phase

11.1.1. Phase I

11.1.1.1. Market Revenue and Forecast

11.1.2. Phase II

11.1.2.1. Market Revenue and Forecast

11.1.3. Phase III

11.1.3.1. Market Revenue and Forecast

11.1.4. Phase IV / Post-Marketing Surveillance

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global EClinical Solutions Market, By End-User

12.1. EClinical Solutions Market, by End-User

12.1.1. Pharmaceutical and Biopharmaceutical Companies

12.1.1.1. Market Revenue and Forecast

12.1.2. Contract Research Organizations (CROs)

12.1.2.1. Market Revenue and Forecast

12.1.3. Academic Research Institutions

12.1.3.1. Market Revenue and Forecast

12.1.4. Hospitals and Clinics

12.1.4.1. Market Revenue and Forecast

12.1.5. Medical Device Companies

12.1.5.1. Market Revenue and Forecast

12.1.6. Regulatory Bodies and Government Research Agencies

12.1.6.1. Market Revenue and Forecast

Chapter 13. Global EClinical Solutions Market, By Therapeutic Area

13.1. EClinical Solutions Market, by Therapeutic Area

13.1.1. Oncology

13.1.1.1. Market Revenue and Forecast

13.1.2. Cardiology

13.1.2.1. Market Revenue and Forecast

13.1.3. Neurology

13.1.3.1. Market Revenue and Forecast

13.1.4. Infectious Diseases

13.1.4.1. Market Revenue and Forecast

13.1.5. Immunology

13.1.5.1. Market Revenue and Forecast

13.1.6. Respiratory

13.1.6.1. Market Revenue and Forecast

13.1.7. Endocrinology (e.g., Diabetes)

13.1.7.1. Market Revenue and Forecast

13.1.8. Rare Diseases / Orphan Drugs

13.1.8.1. Market Revenue and Forecast

13.1.9. Gastroenterology

13.1.9.1. Market Revenue and Forecast

13.1.10. Pain Management

13.1.10.1. Market Revenue and Forecast

13.1.11. Dermatology

13.1.11.1. Market Revenue and Forecast

13.1.12. Other Emerging Therapeutic Area

13.1.12.1. Market Revenue and Forecast

Chapter 14. Global EClinical Solutions Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Solution Type

14.1.2. Market Revenue and Forecast, by Development Phase

14.1.3. Market Revenue and Forecast, by Delivery Mode

14.1.4. Market Revenue and Forecast, by Clinical Trial Phase

14.1.5. Market Revenue and Forecast, by End-User

14.1.6. Market Revenue and Forecast, by Therapeutic Area

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Solution Type

14.1.7.2. Market Revenue and Forecast, by Development Phase

14.1.7.3. Market Revenue and Forecast, by Delivery Mode

14.1.7.4. Market Revenue and Forecast, by Clinical Trial Phase

14.1.8. Market Revenue and Forecast, by End-User

14.1.8.1. Market Revenue and Forecast, by Therapeutic Area

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Solution Type

14.1.9.2. Market Revenue and Forecast, by Development Phase

14.1.9.3. Market Revenue and Forecast, by Delivery Mode

14.1.9.4. Market Revenue and Forecast, by Clinical Trial Phase

14.1.10. Market Revenue and Forecast, by End-User

14.1.11. Market Revenue and Forecast, by Therapeutic Area

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Forecast, by Solution Type

14.2.2. Market Revenue and Forecast, by Development Phase

14.2.3. Market Revenue and Forecast, by Delivery Mode

14.2.4. Market Revenue and Forecast, by Clinical Trial Phase

14.2.5. Market Revenue and Forecast, by End-User

14.2.6. Market Revenue and Forecast, by Therapeutic Area

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Solution Type

14.2.8.2. Market Revenue and Forecast, by Development Phase

14.2.8.3. Market Revenue and Forecast, by Delivery Mode

14.2.9. Market Revenue and Forecast, by Clinical Trial Phase

14.2.10. Market Revenue and Forecast, by End-User

14.2.10.1. Market Revenue and Forecast, by Therapeutic Area

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Solution Type

14.2.11.2. Market Revenue and Forecast, by Development Phase

14.2.11.3. Market Revenue and Forecast, by Delivery Mode

14.2.12. Market Revenue and Forecast, by Clinical Trial Phase

14.2.13. Market Revenue and Forecast, by End-User

14.2.14. Market Revenue and Forecast, by Therapeutic Area

14.2.14.1.

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Solution Type

14.2.15.2. Market Revenue and Forecast, by Development Phase

14.2.15.3. Market Revenue and Forecast, by Delivery Mode

14.2.15.4. Market Revenue and Forecast, by Clinical Trial Phase

14.2.16. Market Revenue and Forecast, by End-User

14.2.16.1. Market Revenue and Forecast, by Therapeutic Area

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Solution Type

14.2.17.2. Market Revenue and Forecast, by Development Phase

14.2.17.3. Market Revenue and Forecast, by Delivery Mode

14.2.17.4. Market Revenue and Forecast, by Clinical Trial Phase

14.2.18. Market Revenue and Forecast, by End-User

14.2.18.1. Market Revenue and Forecast, by Therapeutic Area

14.3. APAC

14.3.1. Market Revenue and Forecast, by Solution Type

14.3.2. Market Revenue and Forecast, by Development Phase

14.3.3. Market Revenue and Forecast, by Delivery Mode

14.3.4. Market Revenue and Forecast, by Clinical Trial Phase

14.3.5. Market Revenue and Forecast, by End-User

14.3.6. Market Revenue and Forecast, by Therapeutic Area

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Solution Type

14.3.7.2. Market Revenue and Forecast, by Development Phase

14.3.7.3. Market Revenue and Forecast, by Delivery Mode

14.3.7.4. Market Revenue and Forecast, by Clinical Trial Phase

14.3.8. Market Revenue and Forecast, by End-User

14.3.9. Market Revenue and Forecast, by Therapeutic Area

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Solution Type

14.3.10.2. Market Revenue and Forecast, by Development Phase

14.3.10.3. Market Revenue and Forecast, by Delivery Mode

14.3.10.4. Market Revenue and Forecast, by Clinical Trial Phase

14.3.11. Market Revenue and Forecast, by End-User

14.3.11.1. Market Revenue and Forecast, by Therapeutic Area

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Solution Type

14.3.12.2. Market Revenue and Forecast, by Development Phase

14.3.12.3. Market Revenue and Forecast, by Delivery Mode

14.3.12.4. Market Revenue and Forecast, by Clinical Trial Phase

14.3.12.5. Market Revenue and Forecast, by End-User

14.3.12.6. Market Revenue and Forecast, by Therapeutic Area

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Solution Type

14.3.13.2. Market Revenue and Forecast, by Development Phase

14.3.13.3. Market Revenue and Forecast, by Delivery Mode

14.3.13.4. Market Revenue and Forecast, by Clinical Trial Phase

14.3.13.5. Market Revenue and Forecast, by End-User

14.3.13.6. Market Revenue and Forecast, by Therapeutic Area

14.4. MEA

14.4.1. Market Revenue and Forecast, by Solution Type

14.4.2. Market Revenue and Forecast, by Development Phase

14.4.3. Market Revenue and Forecast, by Delivery Mode

14.4.4. Market Revenue and Forecast, by Clinical Trial Phase

14.4.5. Market Revenue and Forecast, by End-User

14.4.6. Market Revenue and Forecast, by Therapeutic Area

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Solution Type

14.4.7.2. Market Revenue and Forecast, by Development Phase

14.4.7.3. Market Revenue and Forecast, by Delivery Mode

14.4.7.4. Market Revenue and Forecast, by Clinical Trial Phase

14.4.8. Market Revenue and Forecast, by End-User

14.4.9. Market Revenue and Forecast, by Therapeutic Area

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Solution Type

14.4.10.2. Market Revenue and Forecast, by Development Phase

14.4.10.3. Market Revenue and Forecast, by Delivery Mode

14.4.10.4. Market Revenue and Forecast, by Clinical Trial Phase

14.4.11. Market Revenue and Forecast, by End-User

14.4.12. Market Revenue and Forecast, by Therapeutic Area

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Solution Type

14.4.13.2. Market Revenue and Forecast, by Development Phase

14.4.13.3. Market Revenue and Forecast, by Delivery Mode

14.4.13.4. Market Revenue and Forecast, by Clinical Trial Phase

14.4.13.5. Market Revenue and Forecast, by End-User

14.4.13.6. Market Revenue and Forecast, by Therapeutic Area

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Solution Type

14.4.14.2. Market Revenue and Forecast, by Development Phase

14.4.14.3. Market Revenue and Forecast, by Delivery Mode

14.4.14.4. Market Revenue and Forecast, by Clinical Trial Phase

14.4.14.5. Market Revenue and Forecast, by End-User

14.4.14.6. Market Revenue and Forecast, by Therapeutic Area

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Solution Type

14.5.2. Market Revenue and Forecast, by Development Phase

14.5.3. Market Revenue and Forecast, by Delivery Mode

14.5.4. Market Revenue and Forecast, by Clinical Trial Phase

14.5.5. Market Revenue and Forecast, by End-User

14.5.6. Market Revenue and Forecast, by Therapeutic Area

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Solution Type

14.5.7.2. Market Revenue and Forecast, by Development Phase

14.5.7.3. Market Revenue and Forecast, by Delivery Mode

14.5.7.4. Market Revenue and Forecast, by Clinical Trial Phase

14.5.8. Market Revenue and Forecast, by End-User

14.5.8.1. Market Revenue and Forecast, by Therapeutic Area

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Solution Type

14.5.9.2. Market Revenue and Forecast, by Development Phase

14.5.9.3. Market Revenue and Forecast, by Delivery Mode

14.5.9.4. Market Revenue and Forecast, by Clinical Trial Phase

14.5.9.5. Market Revenue and Forecast, by End-User

14.5.9.6. Market Revenue and Forecast, by Therapeutic Area

Chapter 15. Company Profiles

15.1. PAREXEL International

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Oracle Corp.

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Bioclinica

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Medidata Solution

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. DATATRAK

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. ERT Clinical

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. CRF Health

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. eClinicalWorks

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. OmniComm Systems

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. IBM Watson Health

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global eClinical solutions market size was valued at USD 11.38 billion in 2024 and expected to reach USD 25.85 billion by 2034.

The global eClinical solutions market is poised to grow at a compound annual growth rate (CAGR) 8.10% during the forecast period 2025 to 2034.

Increase in the number of customers adopting eClinical solutions, rising Research and Development (R&D), and rise in government grants to authorize the clinical trials. These solutions are also used in clinical studies where electronic applications enabled with web tools are used to capture the real-time data from clinical trials that provide superior execution and escalate the eClinical solutions market growth.

In 2019, North America held significant value share in the global eClinical solutions market owing to increase in the number of clinical trials in the region. Further, rising government grants for clinical trials, huge funding in R&D activities, technological advancements, along with significant rise in the lifestyle associated diseases are the key factors that propel the industry growth.

The Asia Pacific encountered an escalating CAGR over the forecast timespan due to the rising investment in R&D.

Some of the key players operating in the market are PAREXEL International, Oracle Corp., Bioclinica, Medidata Solution, DATATRAK, ERT Clinical, CRF Health, eClinicalWorks, OmniComm Systems, IBM Watson Health, and eClinical Solutions among others.

Electronic Clinical Outcome Assessment (eCOA) estimated to be the fastest growing product segment over the analysis period due to rising importance of high-quality clinical data.

Cloud-based solutions predicted to exhibit strong growth during the analysis period due to integrated features such as high accessibility, flexibility, and easy data backup.